| Dr Kyle J Hazelwood, MD | |
|
2500 W A St Ste 201, Moscow, ID 83843-6000 | |
| (208) 883-2828 | |
| (208) 882-2179 |
| Full Name | Dr Kyle J Hazelwood |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 17 Years |
| Location | 2500 W A St Ste 201, Moscow, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851549901 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Pullman Regional Hospital | Pullman, WA | Hospital |
| Gritman Medical Center | Moscow, ID | Hospital |
| St Marys Hospital And Clinics | Cottonwood, ID | Hospital |
| Whitman Hospital And Medical Center | Colfax, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Public Hospital District 1-a Of Whitman County | 8325934987 | 50 |
News Archive
A cochlear implant is an electronic device capable of restoring hearing in a profoundly deaf person by directly stimulating the nerve endings in the inner ear. This technology enables people who have become deaf to be able to communicate orally again, even by telephone, and children born deaf to learn to speak and to benefit from normal schooling.
Approximately 10% of low back pain (LBP) sufferers experience persistent pain and significant disability. In a study published in the August issue of Pain, a group of Australian researchers investigating the relevance of health literacy in patients with chronic lower back pain (CLBP) found that LBP-related beliefs and behaviors affect a person's disability more than pain intensity or a standard measure of functional health literacy.
Chiron Corporation announced at a presentation at the 23rd Annual JPMorgan Healthcare Conference that the company anticipates that the UK Medicines and Healthcare products Regulatory Agency (MHRA), accompanied by U.S. Food and Drug Administration (FDA) inspectors as observers, will conduct a series of inspections of Chiron's Liverpool manufacturing facility.
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams every four weeks for the first 12 weeks, followed by 2 mg every eight weeks.
› Verified 3 days ago
| Entity Name | Public Hospital District #1-a Of Whitman County |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366446767 PECOS PAC ID: 8325934987 Enrollment ID: O20040223000506 |
News Archive
A cochlear implant is an electronic device capable of restoring hearing in a profoundly deaf person by directly stimulating the nerve endings in the inner ear. This technology enables people who have become deaf to be able to communicate orally again, even by telephone, and children born deaf to learn to speak and to benefit from normal schooling.
Approximately 10% of low back pain (LBP) sufferers experience persistent pain and significant disability. In a study published in the August issue of Pain, a group of Australian researchers investigating the relevance of health literacy in patients with chronic lower back pain (CLBP) found that LBP-related beliefs and behaviors affect a person's disability more than pain intensity or a standard measure of functional health literacy.
Chiron Corporation announced at a presentation at the 23rd Annual JPMorgan Healthcare Conference that the company anticipates that the UK Medicines and Healthcare products Regulatory Agency (MHRA), accompanied by U.S. Food and Drug Administration (FDA) inspectors as observers, will conduct a series of inspections of Chiron's Liverpool manufacturing facility.
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams every four weeks for the first 12 weeks, followed by 2 mg every eight weeks.
› Verified 3 days ago
| Entity Name | Public Hospital District #1-a Of Whitman County |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1366446767 PECOS PAC ID: 8325934987 Enrollment ID: O20070912000859 |
News Archive
A cochlear implant is an electronic device capable of restoring hearing in a profoundly deaf person by directly stimulating the nerve endings in the inner ear. This technology enables people who have become deaf to be able to communicate orally again, even by telephone, and children born deaf to learn to speak and to benefit from normal schooling.
Approximately 10% of low back pain (LBP) sufferers experience persistent pain and significant disability. In a study published in the August issue of Pain, a group of Australian researchers investigating the relevance of health literacy in patients with chronic lower back pain (CLBP) found that LBP-related beliefs and behaviors affect a person's disability more than pain intensity or a standard measure of functional health literacy.
Chiron Corporation announced at a presentation at the 23rd Annual JPMorgan Healthcare Conference that the company anticipates that the UK Medicines and Healthcare products Regulatory Agency (MHRA), accompanied by U.S. Food and Drug Administration (FDA) inspectors as observers, will conduct a series of inspections of Chiron's Liverpool manufacturing facility.
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams every four weeks for the first 12 weeks, followed by 2 mg every eight weeks.
› Verified 3 days ago
| Entity Name | Kyle Hazelwood Md Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952831083 PECOS PAC ID: 6002188026 Enrollment ID: O20170923000538 |
News Archive
A cochlear implant is an electronic device capable of restoring hearing in a profoundly deaf person by directly stimulating the nerve endings in the inner ear. This technology enables people who have become deaf to be able to communicate orally again, even by telephone, and children born deaf to learn to speak and to benefit from normal schooling.
Approximately 10% of low back pain (LBP) sufferers experience persistent pain and significant disability. In a study published in the August issue of Pain, a group of Australian researchers investigating the relevance of health literacy in patients with chronic lower back pain (CLBP) found that LBP-related beliefs and behaviors affect a person's disability more than pain intensity or a standard measure of functional health literacy.
Chiron Corporation announced at a presentation at the 23rd Annual JPMorgan Healthcare Conference that the company anticipates that the UK Medicines and Healthcare products Regulatory Agency (MHRA), accompanied by U.S. Food and Drug Administration (FDA) inspectors as observers, will conduct a series of inspections of Chiron's Liverpool manufacturing facility.
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams every four weeks for the first 12 weeks, followed by 2 mg every eight weeks.
› Verified 3 days ago
| Entity Name | Inland Orthopaedic Surgery And Sports Medicine Clinic Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952877763 PECOS PAC ID: 5496091605 Enrollment ID: O20190109001105 |
News Archive
A cochlear implant is an electronic device capable of restoring hearing in a profoundly deaf person by directly stimulating the nerve endings in the inner ear. This technology enables people who have become deaf to be able to communicate orally again, even by telephone, and children born deaf to learn to speak and to benefit from normal schooling.
Approximately 10% of low back pain (LBP) sufferers experience persistent pain and significant disability. In a study published in the August issue of Pain, a group of Australian researchers investigating the relevance of health literacy in patients with chronic lower back pain (CLBP) found that LBP-related beliefs and behaviors affect a person's disability more than pain intensity or a standard measure of functional health literacy.
Chiron Corporation announced at a presentation at the 23rd Annual JPMorgan Healthcare Conference that the company anticipates that the UK Medicines and Healthcare products Regulatory Agency (MHRA), accompanied by U.S. Food and Drug Administration (FDA) inspectors as observers, will conduct a series of inspections of Chiron's Liverpool manufacturing facility.
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams every four weeks for the first 12 weeks, followed by 2 mg every eight weeks.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kyle J Hazelwood, MD 2500 W A St Ste 201, Moscow, ID 83843-6000 Ph: (208) 883-2828 | Dr Kyle J Hazelwood, MD 2500 W A St Ste 201, Moscow, ID 83843-6000 Ph: (208) 883-2828 |
News Archive
A cochlear implant is an electronic device capable of restoring hearing in a profoundly deaf person by directly stimulating the nerve endings in the inner ear. This technology enables people who have become deaf to be able to communicate orally again, even by telephone, and children born deaf to learn to speak and to benefit from normal schooling.
Approximately 10% of low back pain (LBP) sufferers experience persistent pain and significant disability. In a study published in the August issue of Pain, a group of Australian researchers investigating the relevance of health literacy in patients with chronic lower back pain (CLBP) found that LBP-related beliefs and behaviors affect a person's disability more than pain intensity or a standard measure of functional health literacy.
Chiron Corporation announced at a presentation at the 23rd Annual JPMorgan Healthcare Conference that the company anticipates that the UK Medicines and Healthcare products Regulatory Agency (MHRA), accompanied by U.S. Food and Drug Administration (FDA) inspectors as observers, will conduct a series of inspections of Chiron's Liverpool manufacturing facility.
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams every four weeks for the first 12 weeks, followed by 2 mg every eight weeks.
› Verified 3 days ago
Edwin M Tingstad, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2500 W A St, Suite 201, Moscow, ID 83843 Phone: 208-883-2828 | |
Dr. Marvin Renell Kym, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2301 W A St, Moscow, ID 83843 Phone: 208-883-1135 Fax: 208-892-0174 | |
Steven E Pennington, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 2500 W A St, Suite 201, Moscow, ID 83843 Phone: 208-883-2828 Fax: 208-882-2179 | |
Dr. Aaron James Vandenbos, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2500 W A St Ste 201, Moscow, ID 83843 Phone: 208-883-2828 Fax: 208-882-2179 | |
Charles A Jacobson, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 2500 W A St, Suite 201, Moscow, ID 83843 Phone: 208-883-2828 Fax: 208-882-2179 | |
Mathew Zane Taylor, M.D, M.P.H. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2500 W A St Ste 201, Moscow, ID 83843 Phone: 208-883-2828 |